Dexrazoxano [Inn-Spanish]
Category
Dexrazoxano [Inn-Spanish] Brand names, Dexrazoxano [Inn-Spanish] Analogs
Dexrazoxano [Inn-Spanish] Brand Names Mixture
Dexrazoxano [Inn-Spanish] Chemical_Formula
C11H16N4O4
Dexrazoxano [Inn-Spanish] RX_link
http://www.rxlist.com/cgi/generic2/dexrazoxane.htm
Dexrazoxano [Inn-Spanish] fda sheet
Dexrazoxano [Inn-Spanish] msds (material safety sheet)
Dexrazoxano [Inn-Spanish] Synthesis Reference
No information avaliable
Dexrazoxano [Inn-Spanish] Molecular Weight
268.269 g/mol
Dexrazoxano [Inn-Spanish] Melting Point
191 - 197 oC
Dexrazoxano [Inn-Spanish] H2O Solubility
Sparingly soluble
Dexrazoxano [Inn-Spanish] State
Solid
Dexrazoxano [Inn-Spanish] LogP
-2.135
Dexrazoxano [Inn-Spanish] Dosage Forms
Liquid; Powder for solution
Dexrazoxano [Inn-Spanish] Indication
For reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer.
Dexrazoxano [Inn-Spanish] Pharmacology
Dexrazoxane is a cardioprotective agent for use in conjunction with doxorubicin indicated for reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin dose.
Dexrazoxano [Inn-Spanish] Absorption
IV administration results in complete bioavailability.
Dexrazoxano [Inn-Spanish] side effects and Toxicity
Intraperitoneal, mouse LD10 = 500 mg/kg. Intravenous, dog LD10 = 2 gm/kg.
Dexrazoxano [Inn-Spanish] Patient Information
No information avaliable
Dexrazoxano [Inn-Spanish] Organisms Affected
Humans and other mammals
![Dexrazoxano_[Inn-Spanish]](http://pharmacycode.com/images/rx/APRD00090.gif)
